It seems nothing (and no one) in our modern world has escaped the changes brought on by a migration to the digital space. In the pharmaceutical and life sciences category, the key opinion leader (KOL) is no exception. Digital opinion leaders (DOLs) have taken an ever-growing role in shaping treatment and disease management discussions. COVID-19 and the global response to the pandemic has hastened the rise of DOLs by restricting in-person activities such as congresses, meetings, and even operating in a clinic.
Diversity, equity, and inclusion practices are sweeping the business world, particularly in diverse countries like the United States. Generational turnover in the US workforce is